<![CDATA[Sanofi ]]>enghttp://www.nasdaqomx.comCopyright (c)2014 NASDAQ OMXhttp://blogs.law.harvard.edu/tech/rssNASDAQ OMX - http://www.nasdaqomx.com/onlineservices@nasdaqomx.com (NASDAQ OMX)onlineservices@nasdaqomx.com (NASDAQ OMX)10<![CDATA[Sanofi ]]>http://www.huginonline.com/France/SANOFI/logo.jpghttp://www.huginonline.com450160<![CDATA[Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis]]>Thu, 21 May 2015 07:00:00 +0200http://cws.huginonline.com/S/152918/PR/201505/1922870_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201505/1922870_5.htmlhttp://hugin.info/152918/R/1922870/689453.pdf<![CDATA[Sanofi and Regeneron Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Presented at the American Thoracic Society 2015 International Conference]]>Mon, 18 May 2015 18:30:00 +0200http://cws.huginonline.com/S/152918/PR/201505/1922218_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201505/1922218_5.htmlhttp://hugin.info/152918/R/1922218/689054.pdf<![CDATA[Sanofi: Annual General Shareholder Meeting of May 4, 2015 ]]>Mon, 4 May 2015 19:01:12 +0200http://cws.huginonline.com/S/152918/PR/201505/1918607_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201505/1918607_5.htmlhttp://hugin.info/152918/R/1918607/686649.pdf<![CDATA[Sanofi delivers Q1 2015 Business EPS(1) growth of 2.6% at CER(2) and 12.8% on a reported basis]]>Thu, 30 Apr 2015 07:30:00 +0200http://cws.huginonline.com/S/152918/PR/201504/1916970_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201504/1916970_5.htmlhttp://hugin.info/152918/R/1916970/685680.pdf<![CDATA[Sanofi: Toujeo® Approved in the European Union for the Treatment of Diabetes in Adults]]>Tue, 28 Apr 2015 15:30:00 +0200http://cws.huginonline.com/S/152918/PR/201504/1915969_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201504/1915969_5.htmlhttp://hugin.info/152918/R/1915969/684944.pdf<![CDATA[Sanofi: FDA Grants Fast Track Designation to Genzyme's Investigational Substrate Reduction Therapy for the Treatment of Fabry Disease]]>Tue, 28 Apr 2015 07:00:00 +0200http://cws.huginonline.com/S/152918/PR/201504/1915454_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201504/1915454_5.htmlhttp://hugin.info/152918/R/1915454/684666.pdf<![CDATA[Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years]]>Thu, 23 Apr 2015 15:00:00 +0200http://cws.huginonline.com/S/152918/PR/201504/1913575_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201504/1913575_5.htmlhttp://hugin.info/152918/R/1913575/683501.pdf<![CDATA[Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)]]>Thu, 19 Mar 2015 07:00:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1904474_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1904474_5.htmlhttp://hugin.info/152918/R/1904474/679070.pdf<![CDATA[Sanofi: Shantha will provide up to 37 million doses of Shan5(TM)]]>Tue, 17 Mar 2015 07:00:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1903845_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1903845_5.htmlhttp://hugin.info/152918/R/1903845/679077.pdf<![CDATA[Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine]]>Sun, 15 Mar 2015 15:58:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1903633_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1903633_5.htmlhttp://hugin.info/152918/R/1903633/679085.pdf